Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021

Video

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork® about the benefits of a conference like the American Association for Cancer Research (AACR) Annual Meeting 2021, and how the collaborative network of thought leaders presents ample opportunity to move the field forward.

Transcription:

What I think the AACR Annual Meeting does is bring together experts from a multitude of fields across the globe to really aim towards one specific goal of understanding cancer and reducing the burden of cancer worldwide. I think that’s a really unique opportunity because these different presentations, mine as well as other posters, other sessions, really afford the opportunity to forge connections and collaborations that you may not have had within your inner network. [Connecting] folks of different expertise may yield just fantastic team science and translational work to answer important questions like these in early-onset colorectal cancer. I’m most excited for that, in addition to presenting these findings, the provocative discussion that will be held both with these results and how we as a field can move forward to really make that precision medicine impact for individual patients overall. From basic science to population science, you’re really bringing together a [group] of experts to really build upon what we already know and go in ways that we may not have thought of individually.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content